Home Cart Sign in  
Chemical Structure| 867160-71-2 Chemical Structure| 867160-71-2

Structure of Linsitinib
CAS No.: 867160-71-2

Chemical Structure| 867160-71-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Linsitinib (OSI-906) is a potent, selective, and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 nM and 75 nM, respectively.

Synonyms: OSI-906

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Linsitinib

CAS No. :867160-71-2
Formula : C26H23N5O
M.W : 421.49
SMILES Code : O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1
Synonyms :
OSI-906
MDL No. :MFCD12912153
InChI Key :PKCDDUHJAFVJJB-UHFFFAOYSA-N
Pubchem ID :11640390

Safety of Linsitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Linsitinib

RTK

Isoform Comparison

Biological Activity

Target
  • IGF-1R

    IGF-1R, IC50:35 nM

  • Insulin Receptor

    Insulin Receptor, IC50:75 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 2 μM 1 day Linsitinib alone or in combination with Dasatinib suppressed the phosphorylation of IGF-1R, Src, and Akt PMC4453276
H226B 1 μM 5 days Linsitinib treatment increased the stability of IGF-1R and Src proteins, enhancing the reciprocal co-activation of IGF-1R and Src PMC4453276
iKras cells 1 μM 24 h Enhanced nab-PTX uptake and cytotoxicity PMC8491539
liv7k oral cancer cell line 10 µM 72 h To test the drug response of Linsitinib in liv7k oral cancer cells, the results showed cell viability under hypoxic and normoxic conditions. PMC6026173
CAFs 5 μM Linsitinib significantly reduced the CAF-mediated inhibition of T cell migration PMC11563680
CAFs 5 μM Linsitinib evidently inhibited fibroblast proliferation PMC11563680
OMM1.3 cells 1 μM 24 h To examine the effect of YM-254890 on UM cell proliferation, results showed that YM-254890 significantly inhibited the proliferation of OMM1.3 cells. PMC9812929
UM001 cells 1 μM 24 h To examine the effect of YM-254890 on UM cell proliferation, results showed that YM-254890 significantly inhibited the proliferation of UM001 cells. PMC9812929
92.1 cells 1 μM 24 h To examine the effect of YM-254890 on UM cell proliferation, results showed that YM-254890 significantly inhibited the proliferation of 92.1 cells. PMC9812929
HCT-15 0.14 μM 96 h Evaluate the effect of Linsitinib on HCT-15 cells, results show that Linsitinib exhibits resistance in HCT-15 cells. PMC11082183
HT115 0.14 μM 96 h Evaluate the effect of Linsitinib on HT115 cells, results show that Linsitinib exhibits resistance in HT115 cells. PMC11082183
LS1034 0.14 μM 96 h Evaluate the effect of Linsitinib on LS1034 cells, results show that Linsitinib exhibits sensitivity in LS1034 cells. PMC11082183
NCI-H508 0.14 μM 96 h Evaluate the effect of Linsitinib on NCI-H508 cells, results show that Linsitinib exhibits sensitivity in NCI-H508 cells. PMC11082183
SNU-61 0.14 μM 96 h Evaluate the effect of Linsitinib on SNU-61 cells, results show that Linsitinib exhibits resistance in SNU-61 cells. PMC11082183
HCC4006 1 μM 72 h Evaluate the effect of Linsitinib combined with Osimertinib on HCC4006 cells, results showed that the combination enhanced the effect of Osimertinib. PMC7490421
HCC827 1 μM 72 h Evaluate the effect of Linsitinib combined with Osimertinib on HCC827 cells, results showed that the combination enhanced the effect of Osimertinib. PMC7490421
H3255 1 μM 72 h Evaluate the effect of Linsitinib combined with Osimertinib on H3255 cells, results showed that the combination enhanced the effect of Osimertinib. PMC7490421

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice NSCLC xenograft model Oral 25 or 50 mg/kg 6 times per week for 3 weeks Combined treatment with Linsitinib and Dasatinib significantly suppressed tumor growth and increased the levels of active caspase-3 in tumor tissues, while decreasing the expression of PCNA, pIGF-1R, and pSrc PMC4453276
Mice Patient-derived xenograft (PDX) models In vitro culture 0.15–20 µM Single dose, lasting 72-96 hours To test the anti-tumor effect of Linsitinib in patient-derived xenograft models, the results showed that Linsitinib has synergistic effects when combined with other drugs. PMC6026173
Mice EO771 and MC38 tumor models Intraperitoneal injection 10 mg/kg Not specified Linsitinib significantly enhanced the therapeutic efficacy of immune checkpoint blockade, reduced tumor growth, and prolonged survival PMC11563680
NSG mice metastatic UM mouse model oral gavage 25-40 mg/kg daily for two weeks To test the inhibitory effect of Linsitinib in combination with YM-254890 on the growth of metastatic uveal melanoma tumors, results showed that the combination treatment significantly inhibited tumor growth. PMC9812929
mice HCC4006 cell line-derived xenograft model oral 50 mg/kg once daily for 10 days Evaluate the effect of Linsitinib combined with Osimertinib on HCC4006 xenograft model, results showed that the combination induced tumor shrinkage and prevented regrowth. PMC7490421
Mice Intracranial xenograft model Oral 50 mg/kg Daily until neurological signs appeared Linsitinib prolonged tumor latency and reduced tumor volumes PMC8110214

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02546544 Relapsed Ewing Sarcoma|Refract... More >>ory Ewing Sarcoma Less << PHASE2 COMPLETED 2016-07-15 Universitè Lyon 1 Claude Berna... More >>rd, Lyon, France|Pediatric Hematology and Oncology, University Hospital Münster, Münster, 48149, Germany|Istituti Ortopedici Rizzoli, Bologna, 40136, Italy|Department of Clinical Oncology, Leiden University Medical Center, Leiden, Postzone K1-P, P.O. Box 9600, Netherlands|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom Less <<
NCT00514007 Advanced Solid Tumors PHASE1 COMPLETED 2012-03-19 Vanderbilt Universtiy Medical ... More >>Center, Nashville, Tennessee, 37232-6307, United States|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom Less <<
NCT00514306 Advanced Solid Tumors PHASE1 COMPLETED 2010-09-20 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States|Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.86mL

2.37mL

1.19mL

23.73mL

4.75mL

2.37mL

References

 

Historical Records

Categories